RT Journal Article
SR Electronic
T1 Fosfomycin for UTIs
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 114
OP 117
DO 10.1136/dtb.2016.10.0429
VO 54
IS 10
YR 2016
UL http://dtb.bmj.com/content/54/10/114.abstract
AB Fosfomycin trometamol is a broad spectrum antibiotic recently marketed in the UK for the treatment of acute uncomplicated lower urinary tract infections (UTIs) in adults1,2 and in adult and adolescent females.3 It is also indicated for prophylaxis in diagnostic and surgical transurethral procedures.1–3 Fosfomycin was discovered in 1969 and the reference drug was first marketed as Monuril in France in 1986.3,4 Although Monuril had UK marketing authorisation, it was never distributed in the UK. However, national guidance included the option of using unlicensed imported fosfomycin.3,5,6 Branded and generic versions of fosfomycin are now available in the UK,1–3,7 and here we review the evidence for their use in the treatment of UTIs.